A Durham man with stage four lung cancer credits a Duke clinical trial for giving him his life back. The trial is funded by ...

The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable ...

The FDA approved agents in MIBC and neuroendocrine tumors and amivantamab/lazertinib continues to shine in NSCLC.

Imfinzi in combination with chemotherapy has been approved in the European Union, EU, for the treatment of adults with ...

The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer ...

AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...

AstraZeneca's drug Imfinzi (NASDAQ: AZN) has received U.S. approval to treat adult patients with muscle-invasive bladder cancer, a significant advancement in cancer therapy. The approval allows ...

Imfinzi-based regimen cuts the risk of disease progression, recurrence, or death by 32% in muscle-invasive bladder cancer. Calquence combo reduced disease progression or death risk by 27% in ...

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s IMFINZI® (durvalumab) combined with gemcitabine and cisplatin for the neoadjuvant treatment of adult patients with ...

In addition to the indication in bladder cancer, IMFINZI is the global standard of care based on OS in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC ...